• Inveready led a €3.5 million financing round for HAWK Biosystems, a Basque precision oncology diagnostics company.
• Co-investors included the European Innovation Council's EIC Fund and the Basque Government's SPRI Group investment vehicle, Basque Fund.
• The round brings HAWK's total funding since inception to approximately €12.5 million.
• Proceeds will expand its pharmaceutical diagnostics business, accelerate international expansion and prepare its entry into clinical diagnostics.
• HAWK expects European regulatory marking in the second quarter of 2027, with its first clinical test targeting non-small cell lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inveready Asset Management SGEIC SA published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.